Rebif® Pregnancy Registry

The requested reference [a69904ae726f6819ffe0d5cee51ce5e92e4068de] no longer exists in our database. It has been replaced by the current reference: [61d3bcdd476f4b8bb71ca9c21738b0f937975245]

Authors EMD Serono -More
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
Links ClinicalTrials.gov
The objective for establishing the Rebif® Pregnancy Registry is to collect prospective outcomes data on women in the United States and Canada who have been exposed to Rebif® during their pregnancies. The primary end point will be the rate of spontaneous abortions in exposed pregnancies. This rate will be compared with the rate of spontaneous abortions in patients with Multiple Sclerosis (MS) whose pregnancies were not exposed to any interferon-beta in a manner consistent with the FDA August 2002 Guidance for Industry: Establishing Pregnancy Exposure Registries
Epistemonikos ID: 9d7a66a0c281d4c816367b61c0d1bda0f2d696e8
First added on: May 04, 2024